Arrowhead Pharmaceuticals Receives TGA Approval for REDEMPLO (Plozasiran) in Australia for Rare Genetic Disorder

Key Takeaways

• Australian TGA approves REDEMPLO (plozasiran) as siRNA therapy for familial chylomicronemia syndrome patients
• Approval expands global access to treatment for rare genetic disorder affecting triglyceride metabolism
• REDEMPLO approved as adjunct to diet therapy for adult FCS patients to reduce dangerous triglyceride levels

---

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasiran), marking a significant expansion of global access for patients with familial chylomicronemia syndrome (FCS).

The approval authorizes REDEMPLO as an adjunct to diet therapy for reducing triglyceride levels in adult patients with FCS, a rare genetic disorder that affects lipid metabolism and can lead to life-threatening complications.

Breakthrough siRNA Technology for Rare Disease

REDEMPLO represents an innovative small interfering RNA (siRNA) medicine that targets the underlying genetic mechanisms of FCS. The condition affects approximately 1 in 1 million people worldwide and is characterized by severely elevated triglyceride levels that can exceed 1,000 mg/dL, compared to normal levels below 150 mg/dL.

Patients with FCS face serious health risks including recurrent pancreatitis, which can be fatal. Traditional treatment options have been limited, making REDEMPLO’s approval particularly significant for the rare disease community.

Market Impact and Global Expansion

The Australian approval follows regulatory successes in other markets, positioning Arrowhead Pharmaceuticals to capture a larger share of the rare disease therapeutics market. The siRNA technology platform underlying REDEMPLO demonstrates the company’s capabilities in developing precision medicines for genetic disorders.

FCS patients in Australia will now have access to a targeted therapy that addresses the root cause of their condition rather than just managing symptoms. The approval also validates Arrowhead’s regulatory strategy for international market expansion.

Clinical Significance

REDEMPLO works by silencing specific genes involved in triglyceride production, offering a novel mechanism of action for FCS treatment. Clinical trials demonstrated significant reductions in triglyceride levels, potentially reducing the risk of pancreatitis episodes that characterize this debilitating condition.

The therapy’s approval as an adjunct to dietary management provides physicians with a comprehensive treatment approach for FCS patients who have historically had limited therapeutic options.

---

Frequently Asked Questions

What is familial chylomicronemia syndrome and how does REDEMPLO help?

FCS is a rare genetic disorder causing extremely high triglyceride levels that can lead to life-threatening pancreatitis. REDEMPLO uses siRNA technology to reduce triglyceride production at the genetic level, addressing the root cause of the condition.

When will REDEMPLO be available to Australian patients?

Following TGA approval, REDEMPLO is now authorized for use in Australia. Availability will depend on healthcare provider prescribing and patient access programs, with rollout expected in the coming months.

How does REDEMPLO compare to existing FCS treatments?

REDEMPLO offers a novel siRNA mechanism targeting genetic causes of FCS, while traditional treatments primarily focus on dietary management and symptom control. This represents the first targeted genetic therapy approach for many FCS patients.